Literature DB >> 33674870

Is there an optimal MRI surveillance schedule for patients with high-grade glioma after standard-of-care-therapy?

Mary Jane Lim-Fat1, Pejman Jabehdar Maralani2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33674870      PMCID： PMC8099464          DOI： 10.1093/neuonc/noab053

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  7 in total

1.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

Review 2.  Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

Authors:  Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

3.  High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  R Stupp; M Brada; M J van den Bent; J-C Tonn; G Pentheroudakis
Journal:  Ann Oncol       Date:  2014-04-29       Impact factor: 32.976

4.  Does Surveillance-Detected Disease Progression Yield Superior Patient Outcomes in High-Grade Glioma?

Authors:  Courtney L Monroe; Sarah Travers; Henok G Woldu; N Scott Litofsky
Journal:  World Neurosurg       Date:  2019-12-09       Impact factor: 2.104

5.  Radiological assessment schedule for high-grade glioma patients during the surveillance period using parametric modeling.

Authors:  So Young Ji; Jongjin Lee; Joo Ho Lee; Soon-Tae Lee; Jae Kyung Won; Jin Wook Kim; Yong Hwy Kim; Tae Min Kim; Seung Hong Choi; Sung-Hye Park; Yongdai Kim; Chul-Kee Park
Journal:  Neuro Oncol       Date:  2021-05-05       Impact factor: 12.300

6.  SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017).

Authors:  M Martínez-Garcia; J Álvarez-Linera; C Carrato; L Ley; R Luque; X Maldonado; M Martínez-Aguillo; L M Navarro; M A Vaz-Salgado; M Gil-Gil
Journal:  Clin Transl Oncol       Date:  2017-10-30       Impact factor: 3.405

Review 7.  Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.

Authors:  Benjamin M Ellingson; Patrick Y Wen; Timothy F Cloughesy
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620
  7 in total
  1 in total

Review 1.  Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas.

Authors:  Jasmin Jo; Martin J van den Bent; Burt Nabors; Patrick Y Wen; David Schiff
Journal:  Neuro Oncol       Date:  2022-07-01       Impact factor: 13.029
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.